A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
A phase 1/2 trial of Pembrolizumab, Carboplatin and Oxaliplatin in advanced solid tumours, run by Astellas Pharma Global Development, Inc., now recruiting.
Overview
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT07730021 by Astellas Pharma Global Development, Inc., with 392 participants planned, started 2026-09-02 and due to reach its primary completion in 2030-02-28. Interventions recorded: ASP388B, Pembrolizumab, Carboplatin, Oxaliplatin and 5-fluorouracil.
Similar pages
not linked directly; found by shared links- TrialA Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Shares Astellas, Carboplatin, Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Shares Astellas, Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialLess Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst in Human Study of T3P-Y058-739 (T3P)
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of YL242 in Subjects With Advanced Solid Tumors
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialN-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
Shares Astellas, Oxaliplatin, Pembrolizumab and the tag pipeline.
- TrialA Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
Shares Astellas, Oxaliplatin and the tag pipeline.